<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04126824</url>
  </required_header>
  <id_info>
    <org_study_id>19-1296</org_study_id>
    <nct_id>NCT04126824</nct_id>
  </id_info>
  <brief_title>Effect of Addition of Steroids on Duration of Analgesia</brief_title>
  <official_title>Prospective Randomized Controlled Clinical Trial: Superior Hypogastric Nerve Block for Pain Control After Uterine Artery Embolization: Effect of Addition of Steroids on Duration of Analgesia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of North Carolina, Chapel Hill</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of North Carolina, Chapel Hill</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to investigate the differences in post-procedural pain scores and
      narcotic use among patients who receive a Superior Hypogastric Nerve Block (SHNB) with and
      without corticosteroid performed as part of the Uterine Artery Embolization (UAE) procedure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Investigators will enroll a total of 28 women undergoing the UAE procedure with 14 subjects
      in each study arm. This investigation is a single blind randomized control trial
      investigating the post-procedural analgesic effect of adding a corticosteroid (Triamcinolone)
      as an adjuvant to a SHNB that contains bupivacaine for patients undergoing UAE, compared to
      patients undergoing nerve block for pain control following UAE with local anesthetic only.
      Before and after the procedure, patients will be asked to complete online surveys in order to
      record their pain score (measured on the Visual Analog Pain Scale), opioid and other pain
      medication use, and other symptoms, such as nausea.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 5, 2019</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Pain Intensity Measure (mm)</measure>
    <time_frame>Baseline, 240 hours</time_frame>
    <description>The pain intensity is assessed using a visual analogue scale (VAS), which is a horizontal line 100 mm in length. Subjects mark the VAS with a single vertical line to indicate their current pain level, with 0 mm representing &quot;No Pain&quot; and 100 mm representing &quot;Worst Possible Pain&quot;.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Uterine Fibroids</condition>
  <condition>Adenomyosis</condition>
  <arm_group>
    <arm_group_label>Bupivacaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>During the Uterine Artery Embolization (UAE) procedure, participants in this arm receive bupivacaine and contrast to enable visualization of the nerve block under fluoroscopy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bupivacaine and Triamcinolone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>During the Uterine Artery Embolization (UAE) procedure, participants in this arm receive bupivacaine plus triamcinolone mixed with contrast to enable visualization of the nerve block under fluoroscopy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Triamcinolone</intervention_name>
    <description>40 mg triamcinolone administered as a Superior Hypogastric Nerve Block (SHNB)</description>
    <arm_group_label>Bupivacaine and Triamcinolone</arm_group_label>
    <other_name>Kenalog</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine</intervention_name>
    <description>0.5% bupivacaine (20 mL) administered as a Superior Hypogastric Nerve Block (SHNB).</description>
    <arm_group_label>Bupivacaine</arm_group_label>
    <arm_group_label>Bupivacaine and Triamcinolone</arm_group_label>
    <other_name>Marcaine, Exparel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Iohexol contrast</intervention_name>
    <description>The appropriate amount of contrast to enable visualization of the nerve block under fluoroscopy given as a Superior Hypogastric Nerve Block (SHNB) will be administered.</description>
    <arm_group_label>Bupivacaine</arm_group_label>
    <arm_group_label>Bupivacaine and Triamcinolone</arm_group_label>
    <other_name>Omnipaque</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  females

          -  aged between 30 and 60 years

          -  diagnosed with symptomatic uterine fibroids and/or adenomyosis and scheduled to
             undergo UAE procedure

        Exclusion Criteria:

          -  Contraindications to UAE

          -  SHNB is deemed unsafe for the patient

          -  Allergies to local anesthetic or steroid agent

          -  History of inflammatory bowel disease or ulcerative colitis

          -  Uncorrectable abnormal coagulation profile

          -  Diabetes mellitus
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jessica Stewart, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of North Carolina</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hannah P Mignosa</last_name>
    <phone>984-215-4963</phone>
    <email>hannah_mignosa@med.unc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Markeela Lipscomb</last_name>
    <phone>919-843-3670</phone>
    <email>markeela_lipscomb@med.unc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of North Carolina</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hannah Mignosa</last_name>
      <phone>984-215-4963</phone>
      <email>hannah_mignosa@med.unc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Markeela Lipscomb</last_name>
      <phone>919-843-3670</phone>
      <email>markeela_lipscomb@med.unc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Jessica Stewart, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>October 7, 2019</study_first_submitted>
  <study_first_submitted_qc>October 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 15, 2019</study_first_posted>
  <last_update_submitted>June 24, 2020</last_update_submitted>
  <last_update_submitted_qc>June 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Uterine Artery Embolization</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leiomyoma</mesh_term>
    <mesh_term>Adenomyosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Triamcinolone</mesh_term>
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Deidentified data may be made available upon request once the final manuscript is published.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>Deidentified individual data that supports the results will be shared beginning 9 to 36 months following publication.</ipd_time_frame>
    <ipd_access_criteria>An investigator who proposes to use the data must have approval from an IRB, IEC, or REB, as applicable, and an executed data use/sharing agreement with UNC.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

